Stephen L. Eck - 15 Feb 2025 Form 4 Insider Report for MACROGENICS INC (MGNX)

Role
Chief Medical Officer
Signature
Beth A. Smith, Attorney-in-fact
Issuer symbol
MGNX
Transactions as of
15 Feb 2025
Net transactions value
-$12,652
Form type
4
Filing time
19 Feb 2025, 16:20:46 UTC
Previous filing
11 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MGNX Common Stock Options Exercise $0 +16,665 +94% $0.000000 34,319 15 Feb 2025 Direct F1
transaction MGNX Common Stock Tax liability $12,652 -4,942 -14% $2.56 29,377 15 Feb 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGNX Restricted Stock Unit Options Exercise $0 -16,665 -50% $0.000000 16,665 15 Feb 2025 Common Stock 16,665 $0.000000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 15, 2023, the reporting person was granted 50,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis.